Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Ironwood Pharmaceuticals (IRWD) stock in plain English

Free brief · no signupStart here
IRWDPublished Nov 12, 2026
Ironwood Pharmaceuticals Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells prescription treatments for gastrointestinal conditions and advances therapies for rare bowel diseases.
Assets:
Linzess brandCo-promoted gastrointestinal drug generating most company collaboration revenue
Apraglutide programLate-stage synthetic peptide candidate targeting rare short bowel syndrome
Boston headquartersCentral corporate office directing clinical trials and commercial partnerships
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

95
OPS ScoreOperating finances
Latest quote
-1.46%$4.71
$779.74M
5.3×
$399.87M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was IRWD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Ironwood Pharmaceuticals (IRWD) do?

Ironwood Pharmaceuticals Inc (IRWD) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells prescription treatments for gastrointestinal conditions and advances therapies for rare bowel diseases. Partners with larger pharmaceutical makers to co-develop and sell prescription treatments for gastrointestinal diseases. It is worth $779.74M on the market and sold $399.87M over the last year.

Market cap
$779.74M
P/E ratio
5.3×
Annual sales
$399.87M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 12, 2026

Brands and businesses behind IRWD

  • Linzess: Linzess treats irritable bowel syndrome and constipation, generating revenue through commercial partnership profit splits with AbbVie.

IRWD’s flags, in plain English

Each flag is a number from Ironwood Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Stupid Cash

Can pay this year's bills 6.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Fat Margins

Profit margin of 37.4%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Wide Gross Margin

Gross margin of 99.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth Cooling

Sales growth slowed to -5.3% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about IRWD

How big is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals’ market cap is $779.74M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $399.87M: what customers paid the company over the last year, before any costs.

What is IRWD’s P/E ratio?

IRWD’s P/E ratio is 5.3×. Investors pay about 5.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with IRWD?

Revenue depends heavily on collaboration profits generated by a single drug named Linzess. That is one risk on Ironwood Pharmaceuticals’ card. Its first risk flag is Growth Cooling, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Ironwood Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IRWD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card